Jonathan E. Freeman serves as Executive at RXi Pharmaceuticals Corp, where they oversee executive responsibilities. Since joining the company, Jonathan E. Freeman has executed 8 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Feb 5, 2026 involved receiving (via award) 16,600 shares valued at $0.
Jonathan E. Freeman currently holds 32,655 shares of RXi Pharmaceuticals Corp (RXII), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Jonathan E. Freeman has been a net neutral trader of RXII stock. They have purchased $0 and sold $0 worth of shares.
Jonathan E. Freeman's most recent insider trade was on Feb 5, 2026, when they sold 16,600 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Sep 11, 2024 | PHIO | $0 | Award | 1,000 | $N/A | Discretionary |
| Feb 17, 2023 | PHIO | $0 | Award | 1,500 | $N/A | Discretionary |
| Feb 15, 2022 | PHIO | $0 | Award | 10,000 | $N/A | Discretionary |
| Mar 1, 2021 | PHIO | $0 | Award | 10,000 | $N/A | Discretionary |
| Feb 13, 2019 | PHIO | $0 | Award | 10,000 | $N/A | Discretionary |
| Aug 1, 2018 | RXII | $0 | Award | 10,000 | $N/A | Discretionary |